Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -25.03% is 1590% below its 5-year average of -1.48%, near the low end of its 5-year range (-25.03%–2.43%).
As of the fiscal period ended Tuesday, June 30, 2026. 73.40% below its 12-month average of -14.43%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -25.03%.
RETURN ON EQUITY (ROE)
-25.03%
RETURN ON EQUITY (ROE) AVG TTM
-14.43%
RETURN ON EQUITY (ROE) AVG 3Y
-2.75%
RETURN ON EQUITY (ROE) AVG 5Y
-1.48%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-73.40%
CURRENT VS 3Y AVG
-808.47%
CURRENT VS 5Y AVG
-1590.06%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-37.66%
median of 434 covered companies
CURRENT VS SECTOR MEDIAN
+33.54%
vs the sector median at left
Cytek Biosciences, Inc.
Market Cap
$786.48M
Return on Equity (ROE)
-25.03%
TTM Avg
-14.43%
3Y Avg
-2.75%
5Y Avg
-1.48%
Market Cap
$780.95M
Return on Equity (ROE)
-16.56%
TTM Avg
0.55%
3Y Avg
-10.56%
5Y Avg
-13.37%
Market Cap
$776.24M
Return on Equity (ROE)
-31.97%
TTM Avg
-50.13%
3Y Avg
-87.97%
5Y Avg
-79.93%
Market Cap
$775.72M
Return on Equity (ROE)
-35.07%
TTM Avg
-26.66%
3Y Avg
-24.19%
5Y Avg
-5.48%
Market Cap
$774.32M
Return on Equity (ROE)
-40.21%
TTM Avg
-52.14%
3Y Avg
-52.14%
5Y Avg
-52.14%
Market Cap
$767.46M
Return on Equity (ROE)
-22.36%
TTM Avg
-60.32%
3Y Avg
-42.71%
5Y Avg
-132.49%
Market Cap
$812.20M
Return on Equity (ROE)
12.32%
TTM Avg
19.75%
3Y Avg
23.44%
5Y Avg
27.16%
Market Cap
$819.44M
Return on Equity (ROE)
-13.30%
TTM Avg
11.91%
3Y Avg
154.09%
5Y Avg
54.89%
Market Cap
$749.55M
Return on Equity (ROE)
-70.19%
TTM Avg
-78.37%
3Y Avg
-123.45%
5Y Avg
-79.18%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cytek Biosciences, Inc. (CTKB) | $786.48M | -25.03% | -14.43% | -2.75% | -1.48% |
| AdaptHealth Corp. (AHCO)vs › | $780.95M | -16.56% | 0.55% | -10.56% | -13.37% |
| Geron Corporation (GERN)vs › | $776.24M | -31.97% | -50.13% | -87.97% | -79.93% |
| Design Therapeutics, Inc. (DSGN)vs › | $775.72M | -35.07% | -26.66% | -24.19% | -5.48% |
| Attovia Therapeutics, Inc. (ATTO)vs › | $774.32M | -40.21% | -52.14% | -52.14% | -52.14% |
| Avalo Therapeutics, Inc. (AVTX)vs › | $767.46M | -22.36% | -60.32% | -42.71% | -132.49% |
| InMode Ltd. (INMD)vs › | $812.20M | 12.32% | 19.75% | 23.44% | 27.16% |
| Gyre Therapeutics, Inc. (GYRE)vs › | $819.44M | -13.30% | 11.91% | 154.09% | 54.89% |
| Candel Therapeutics, Inc. (CADL)vs › | $749.55M | -70.19% | -78.37% | -123.45% | -79.18% |
| Ardelyx, Inc. (ARDX)vs › | $837.43M | -37.38% | -29.74% | -41.86% | -72.28% |
ROE
-25.0%
ROA
-18.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -25.03% |
| 2026-03-31 | -22.59% |
| 2025-12-31 | -19.47% |
| 2025-09-30 | -3.39% |
| 2025-06-30 | -1.70% |
| 2025-03-31 | -2.96% |
| 2024-12-31 | -1.52% |
| 2024-09-30 | -2.64% |
| 2024-06-30 | -4.51% |
| 2024-03-31 | -2.93% |
| 2023-12-31 | -3.09% |
| 2023-09-30 | -3.40% |
| 2023-06-30 | -1.41% |
| 2023-03-31 | -0.52% |
| 2022-12-31 | 0.61% |
| 2022-09-30 | -0.51% |
| 2022-06-30 | -0.58% |
| 2022-03-31 | 0.22% |
| 2021-12-31 | 0.74% |
| 2021-09-30 | 2.43% |
